245 related articles for article (PubMed ID: 32625210)
1. Oral Preconditioning of Donors After Brain Death With Calcineurin Inhibitors vs. Inhibitors of Mammalian Target for Rapamycin in Pig Kidney Transplantation.
Abbasi Dezfouli S; Nikdad M; Ghamarnejad O; Khajeh E; Arefidoust A; Mohammadi S; Majlesara A; Sabagh M; Gharabaghi N; Kentar M; Younsi A; Eckert C; Poth T; Golriz M; Mehrabi A; Nickkholgh A
Front Immunol; 2020; 11():1222. PubMed ID: 32625210
[No Abstract] [Full Text] [Related]
2. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
[TBL] [Abstract][Full Text] [Related]
3. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Witzke O; Wolters HH; Suwelack B; Klehr HU; Stangl M; Hauser IA; Nadalin S; Porstner M; May C; Paulus EM; Sommerer C;
Transpl Int; 2014 Nov; 27(11):1192-204. PubMed ID: 25070687
[TBL] [Abstract][Full Text] [Related]
5. Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia-reperfusion injury in a rat syngenic kidney transplantation model.
Cicora F; Roberti J; Vasquez D; Guerrieri D; Lausada N; Cicora P; Palti G; Chuluyan E; Gonzalez P; Stringa P; Raimondi C
Clin Exp Immunol; 2012 Jan; 167(1):169-77. PubMed ID: 22132896
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
7. Influence of a modified preservation solution in kidney transplantation: A comparative experimental study in a porcine model.
Golriz M; Fonouni H; Kuttymuratov G; Esmaeilzadeh M; Rad MT; Jarahian P; Longerich T; Faridar A; Abbasi S; Mehrabi A; Gebhard MM
Asian J Surg; 2017 Apr; 40(2):106-115. PubMed ID: 26337376
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin Inhibitor in NEuRoloGically deceased donors to decrease kidney delayed graft function study: study protocol of the CINERGY Pilot randomised controlled trial.
D'Aragon F; Selzner M; Breau R; Masse MH; Lamontagne F; Masse M; Chassé M; Carrier FM; Cardinal H; Chaudhury P; Weiss M; Lauzier F; Turgeon AF; Frenette AJ; Bolduc B; Ducharme A; Lamarche C; Couture E; Holdsworth S; Bertholz L; Talbot H; Slessarev M; Luke P; Boyd JG; Shamseddin MK; Burns KEA; Zaltzman J; English S; Knoll G; Dhanani S; Healey A; Hanna S; Rochwerg B; Oczkowski SJW; Treleaven D; Meade M;
BMJ Open; 2024 Jun; 14(6):e086777. PubMed ID: 38871657
[TBL] [Abstract][Full Text] [Related]
9. [Effects of N-acetylcysteine on apoptosis induced by myocardial ischemia reperfusion injury in rats' heart transplantation].
Yi X; Cui X; Wu P; Wang S; Wang G; Yang X; Yang F; Zheng S; Li Z
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2013 Oct; 27(10):1234-9. PubMed ID: 24397138
[TBL] [Abstract][Full Text] [Related]
10. Promising effects of ischemic preconditioning in renal transplantation.
Torras J; Herrero-Fresneda I; Lloberas N; Riera M; Ma Cruzado J; Ma Grinyó J
Kidney Int; 2002 Jun; 61(6):2218-27. PubMed ID: 12028463
[TBL] [Abstract][Full Text] [Related]
11. Ischemic preconditioning improves rat kidney allograft function after ischemia/reperfusion injury: the role of tumor necrosis factor-alpha.
Jia RP; Xie JJ; Luo FY; Zhu JG
Transplant Proc; 2008 Dec; 40(10):3316-20. PubMed ID: 19100380
[TBL] [Abstract][Full Text] [Related]
12. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
13. Fenoldopam preconditioning: role of heme oxygenase-1 in protecting human tubular cells and rodent kidneys against cold-hypoxic injury.
Salahudeen AK; Yang M; Huang H; Dore S; Stec DE
Transplantation; 2011 Jan; 91(2):176-82. PubMed ID: 21076374
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk in kidney transplant recipients receiving mammalian target of rapamycin inhibitors.
Watorek E; Szymczak M; Boratynska M; Patrzalek D; Klinger M
Transplant Proc; 2011 Oct; 43(8):2967-9. PubMed ID: 21996202
[TBL] [Abstract][Full Text] [Related]
15. Conversion of calcineurin inhibitors with mammalian target of rapamycin inhibitors after kidney transplant.
Nikoueinejad H; Soleimani A; Mirshafiey A; Amirzargar A; Sarrafnejad A; Kamkar I; Einollahi B
Exp Clin Transplant; 2013 Feb; 11(1):12-6. PubMed ID: 23387537
[TBL] [Abstract][Full Text] [Related]
16. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
[TBL] [Abstract][Full Text] [Related]
17. Low-dose In Situ Perfusion With Euro-Collins Solution Is Effective for the Procurement of Marginal Kidney Grafts From Donation After Circulatory Death Donors.
Tojimbara T; Yashima J; Shirai H; Masaki N; Tonsho M; Teraoka S
Transplant Proc; 2019 Oct; 51(8):2520-2522. PubMed ID: 31395361
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin donor pre-treatment in a model of brain death and allogeneic kidney transplantation in rat.
Hoeger S; Benck U; Petrov K; Waldherr R; Schnuelle P; Yard BA; Krämer BK; Gottmann U
Ann Transplant; 2012; 17(1):79-85. PubMed ID: 22466912
[TBL] [Abstract][Full Text] [Related]
19. Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers.
Cheung CY; Man Ma MK; Chak WL; Chau KF; Tang SCW
Oncotarget; 2017 Jul; 8(27):44833-44841. PubMed ID: 28160552
[TBL] [Abstract][Full Text] [Related]
20. Donor pre-treatment with everolimus or cyclosporine does not reduce ischaemia-reperfusion injury in a rat kidney transplant model.
Martinez-Palli G; Hirose R; Liu T; Xu F; Dang K; Feiner J; Serkova NJ; Niemann CU
Nephrol Dial Transplant; 2011 Jun; 26(6):1813-20. PubMed ID: 21068143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
